Risk of HCV infection associated with hospital-based invasive procedures: a systematic review and meta-analysis

Paul Henriot[1,2], Mathieu Castry[3], Liem Binh Luong Nguyen[4], Yusuke Shimakawa[2,5], Kévin Jean[1,2], Laura Temime[1,2]

[1]MESuRS Laboratory, Conservatoire national des arts et métiers, 292 rue Saint-Martin, 75003, Paris

[2]PACRI Unit, Conservatoire national des arts et métiers / Institut Pasteur, France

[3]Université de Paris, Inserm, IAME, F-75006 Paris, France

[4]CIC Cochin, AP-HP, Paris

[5]Unité d'Epidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

Correspondence to : Paul Henriot, Conservatoire national des arts et métiers (MESuRS Laboratory), 292 rue Saint-Martin, 75003, Paris. **email address :** paul.henriot@lecnam.net

Summary

Background: Healthcare settings, where invasive procedures are frequently performed, may play an important role in the transmission dynamics of blood-borne pathogens when compliance with infection control precautions remains suboptimal. This study aims at better understanding and quantifying the role of hospital-based invasive procedures on hepatitis C virus (HCV) transmission.

Methods: We conducted a systematic review and meta-analysis to identify recent studies reporting association measures of HCV infection risk that are linked to iatrogenic procedures performed in hospital settings. Based on expert opinion, invasive procedures were categorized into 10 groups for which pooled measures were calculated. Finally, the relationship between pooled measures and the country-level HCV prevalence or the Healthcare Access and Quality (HAQ) index was assessed in meta-regressions.

Findings: A total of 71 studies were included in the analysis. The most evaluated procedures were blood transfusion and surgery (60 and 37 studies, respectively). The pooled odds ratio (OR) of HCV infection varied widely, ranging from 1·46 (95%CI: 1·14-1·88) for dental procedures to 5·86 (1·26-27·24) for haemodialysis. The OR for blood transfusion was higher for transfusions performed before 1998 (3·77, 2·42-5·88) than for those without a specified date (2·26, 1·81-2·81). Finally, the country-level overall risk for all procedures was significantly associated with HCV prevalence, but not with the HAQ index. In procedure-specific analyses, the HCV infection risk was significantly negatively associated with the HAQ for endoscopy and positively associated with HCV prevalence for endoscopy and surgery.

Interpretation: Various invasive procedures were documented to be significantly associated with HCV infection. Our results provide a ranking of procedures in terms of HCV risk that may be used for prioritization of infection control measures, especially in high HCV prevalence settings.

Funding: INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites)

Research in context

Evidence before this study

We searched PubMed for systematic review or meta-analyses articles published between Jan 1, 2000 and Oct 31, 2021, and focused on iatrogenic risk factors associated with HCV infection in hospitalized patients, using “hepatitis C”, “risk” and “hospital” as keywords. We found a single meta-analysis assessing HCV risk factors and reporting pooled risks estimates for hospital-based procedures. This meta-analysis was not specific to in-hospital procedures, was based on articles published between 1989 and 2013, and did not strictly follow PRISMA guidelines.

Added value of this study

Our study presents an up-to-date assessment of the risks of HCV infection associated with different hospital-based procedures. Results suggest that iatrogenic HCV infection risk remains important, even considering recent studies. We underline the importance of this risk in high prevalence settings and provide a potential prioritization of procedures associated with HCV infection that may help implementing infection control measures efficiently.

Implications of all the available evidence

This study shows that iatrogenic procedures remain at risk of transmitting blood-borne pathogens, in particular HCV. This highlights the importance for hospitals to implement stronger control measures, especially in high HCV prevalence settings, even considering the availability of direct acting antivirals which represent a very expensive solution. These results could be used in modelling studies to help find optimal and efficient control measures to reduce in-hospital HCV transmission.

Introduction

Hepatitis C virus (HCV) is mainly a blood-borne virus associated with an estimated global sero-prevalence of 2·5%.[1] However, wide between-country discrepancies are observed, with Egypt and Pakistan having high anti-HCV prevalence in the general population.[1] Chronic HCV infection may lead to serious disease complications like cirrhosis or hepatocellular carcinoma (HCC), with about 20% developing HCC.[2] Highly effective and well-tolerated direct-acting antiviral treatments (DAAs) are now available, but these treatments remain costly. An estimated 79% of people chronically infected with HCV worldwide still did not know their status in 2019,[3] limiting the population impact of DAAs. In addition, the residual risk of HCC is suspected to remain relatively high among patients who cured chronic HCV infection.[4] Moreover, HCV treatment should not be the only way of fighting new infections, as accumulating evidence suggests that even after treatment reinfection can occur, especially in people who inject drugs.[5] Therefore, prevention measures to limit the risk of HCV contamination remain key in the global response against HCV.[6]

Although injection drug use has been established to be the most important risk factor for acquiring a new HCV infection,[7] healthcare settings may play an important role in HCV transmission dynamics, due to the high frequency of invasive procedures and over-representation of HCV-infected individuals among hospitalized patients. Medical procedures have been linked to multiple HCV outbreaks worldwide, for instance in Egypt[8], India[9] or the United States.[10] In healthcare settings where compliance with infection control measures is suboptimal, patients may still become infected following procedures such as blood transfusion or haemodialysis.[11,12] Overall, previous hospitalization remains a major risk factor for HCV infection in many countries.[13]

In this context, a better control of hospital-acquired infections would significantly help in the fight against HCV epidemics. This requires a clear understanding of the role played by different at-risk procedures within healthcare settings, in order to effectively focus control measures and efforts. Here, we conduct a systematic review and meta-analysis of the current evidence regarding the strength of association between HCV infection and a wide array of hospital-based invasive procedures, in order to propose a prioritization of iatrogenic procedures and better understand their role in HCV transmission.

Methods

Search strategy and selection criteria

We searched three online databases (PubMed, Web of Science, Scopus) for studies published between January 2000 and December 2020 using the keywords “hepatitis”, “risk factor”, “hospital”, and “procedure” as main lexical fields (Suppl Table S1). This study was registered in PROSPERO in February 2021 (ID: CRD42021224886), and is reported according to PRISMA guidelines.

Studies were eligible if: (i) Exposure group was composed of hospitalized adults in- or out-patients; (ii) they reported measures of association (odds ratios, ORs; risk ratios, RRs; or prevalence ratios, PRs) between one or more health-care procedures and the risk of HCV infection (defined by detection of either HCV RNA or HCV antibodies). This later criterion implies that studies had to include a comparison group unexposed to these procedures. All study designs were allowed during study selection.

Studies were excluded if: (i) They were focused on paediatric patients, drug users, or blood donors only, to avoid bias linked to either age-constraint or repetitive at-risk habits; (ii) patient inclusion started before 2000; (iii) they were not written in French or English; (iv) they did not present original results.

Based on the inclusion and exclusion criteria, articles titles and abstracts were screened by two independent investigators (MC and PH) using the Covidence review tool.[14] Full-text articles were then retrieved and assessed for eligibility by the same two authors. Any conflict in articles screening or full-text assessment were resolved by a third senior researcher (KJ or LT).

For each study, the following data were extracted by PH: (i) Total number of patients; (ii) patients type; (iii) study design; (iv) measures of association and sample size of the control/exposed groups

Data analysis

After studies selection, the procedures reported were aggregated into 10 groups based on medical expert opinion (Table 1). Risk of blood borne infection was supposed to be homogeneous within these groups. When two or more procedures classified in the same group were assessed within the same study, a pooled group-level measure was computed using a fixed-effect model since these estimates were calculated based on the same population. Measures associated with the same procedure but reported across different populations (e.g., by gender) were considered independently.

***Table 1*: Aggregation of procedures found within selected articles**

Group	Procedures within group
Surgery	Surgery, operation, bloody operation, splenectomy, laparoscopy, organ biopsy, biopsy, ligation of oesophageal varices, caesarean section
Transplantation	Transplantation, renal transplantation
Blood transfusion	dated blood transfusion / non-dated blood transfusion
Intravenous (IV) / Catheter	Cholangiography, IV pyelography, IV injection, IV-line, sclerotherapy, catheter, central venous catheter, cannula, phlebotomy
Haemodialysis	Haemodialysis
Wound care	Wound suture, wound care
Injection	IM injection, percutaneous injection, subcutaneous injection, injection/vaccination, injection
Other procedures	EMG, haemorrhoids treatment, tapping ascites, abscess drainage, abortion
Endoscopy	Endoscopy, colonoscopy, gastroscopy
Dental care	Tooth extraction, dental anaesthesia, dental procedure, dental care, tooth filling

We performed a meta-analysis to compute pooled OR estimates of the risk of HCV infection associated with each procedure using the R “meta” package. Measures that were not ORs (RRs and PRs) were considered to be equivalent to ORs and included in the same analyses. When both adjusted ORs (AORs) and crude ORs (CORs) were available in the same study, the AORs were preferred. If risk estimates were available for dated and undated (without specified date) blood transfusion, estimates associated with undated blood transfusion were preferred.

In a second step, pooled ORs for low HCV prevalence (< 5%) and high HCV prevalence (> %5) countries were compared through subgroups analysis for each procedure group. Prevalence data for each country were collected from the MapCrowd online global data on hepatitis C (Suppl Table S7).[15] Pooled ORs were stratified by country for the 2 most represented procedure groups.

Thirdly, the pooled OR for blood transfusion based on transfusions performed with either recent dated an unspecified date of realization was compared to the one based on transfusions performed before 1998, which is the latest cut-off date used within selected articles. We assumed cut-off dates found in the studies selected to reflect local implementation of mandatory HCV screening in blood donors.

In the last step of our analysis, meta-regressions were performed to investigate the potential effect modifier of: (i) the HCV prevalence level, and (ii) the Healthcare access and quality (HAQ) index, a 0 to 100 score estimating the strength of healthcare quality and access based on amenable mortality data in each country (Suppl Table S7).[16]

Pooled estimates were computed using random effect models considering our aim to generalize results beyond the selected studies. Each of these estimates was calculated together with the heterogeneity level (I^2 statistics).

A bias analysis was conducted (by PH) on the articles included. Nine bias assessment criteria were adapted from Lam *et al.* (2016c)[17], and publication bias was assessed by testing for asymmetry in the overall and procedure-specific funnel plots.[18] In addition, subgroups analyses were performed to compare estimates between cohort and non-cohort studies.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

Results



***Figure 1*: Study selection**

165 Among the 1,961 initially identified studies, 71 were included in the review[18-89], as described in the
166 flow diagram (Fig 1). The total number of participants across all selected studies was 120,734.



167

168 ***Figure 2*: Study characteristics.** (a) Time changes in the number of studies published between
169 2000 and 2020; (b) Distribution of patient types across the included studies; (c) Number of
170 studies per country; (d) Distribution of studies designs.

171 Fig. 2.a shows an increase of publications related to HCV risk assessment within hospitals between
172 2000 and 2015, while the number of publications remained stable between 2015 and 2020. Together,
173 Pakistan (fourteen studies) and Egypt (nine studies) represented one third of all included studies
174 (Fig2.c). Over a fifth of studies were focused on haemodialysis patients (21·9%) (Fig 2.b). Most studies
175 were cross-sectional (55%) or case-control (22·5%) studies (Fig 2d).

176 Forty-five different procedures were assessed (Table 1). The number of observations per each of the
177 ten procedure groups ranged from five to sixty, with surgery and transfusion as the largest groups
178 (respectively 37 and 60) (Fig. 3, Table S6). All pooled ORs were significantly superior to one, except for
179 endoscopy.

180 Subgroup analyses showed that the risk of HCV infection differed significantly according to procedure
181 groups (Q = 24·16, p-value=0·0041), with pooled OR estimates ranging from 1·46 (CI 95% [1·14-1·88])
182 for dental procedure up to 5·87 (CI 95% [1·26-27·24]) for haemodialysis. The IV/Catheter, wound care
183 and transplantation groups had OR estimates ranging from 2·86 (CI 95% [1·66-4·93] for IV/Catheter)
184 to 3·84 (CI 95% [2·07-7·12] for wound care), representing moderate/high risk groups. The surgery,

185 other procedure and transfusion groups had intermediate pooled ORs, with estimates of 2·21 (CI 95%
186 [1·75-2·8]), 2·22 (CI 95% [1·3-3·77]) and 2·59 (CI 95% [2·09-3·21]) respectively. Injection was associated
187 with a low/moderate risk of HCV infection with an estimate of 1·69 (CI 95% [1·19-2·41]). Finally, the
188 dental procedure and endoscopy groups presented the lowest risks of getting HCV infected (1·46 CI
189 95% [1·14-1·88] and 1·48 CI 95% [0·95-2·3] respectively).

190



191 ***Figure 3*: Forest plot reporting pooled OR estimates for HCV infection risk associated with**
192 **different groups of iatrogenic procedures.** Points correspond to average estimates and error
193 bars correspond to 95% CI of these estimates. The solid line represents the limit for which OR
194 = 1 and the dotted line the value of the overall estimate. The total number of observations
195 used for each pooled OR calculation is specified in the column *N* and represented as the size
196 of the grey area around each point estimate; the heterogeneity for each estimation is depicted
197 in the column I^2. A given study could be used in the OR estimation of multiple procedures
198 groups. Procedures are sorted based on the value of their associated mean estimate, from the
199 highest to the lowest.

200 Country-stratified analyses were performed for transfusion and surgery (Fig 4). For these two
201 procedure groups, estimated ORs varied widely between countries. The highest risk of HCV infection
202 by blood transfusion was reported in Germany (OR = 5·4 CI 95% [2·7-10·9]) but this estimate
203 corresponds to only one study and is associated with transfusions performed before 1991. Other
204 countries associated with relatively high HCV infection average risk for blood transfusion were Egypt
205 (OR = 5·2 CI 95% [1·9-14·3]), Iran (5·1 [1-25]), Turkey (4·5 [1·7-11·9]) and Malaysia (4 [2·2-7·3]).
206 Nevertheless, associated confidence intervals were quite wide. There were less high-risk countries
207 concerning surgery, for which Egypt and India were associated with the highest risk (4·3 [2-9] and 4·6
208 [0·8-26]).

209 Overall, average estimates were always higher in high prevalence countries (Fig 6), but a significant
210 difference was observed for endoscopy (Q=9·40, p-value=0·0022), surgery (Q=4·54, p-value=0·0331)
211 and injection (Q=5·40, p =0·0201) only. These results were supported by procedure-specific meta-
212 regressions (Suppl Table S3) showing prevalence to have a significant positive effect on the OR level of
213 the endoscopy (p=0·004) and surgery (p=0·011) groups. Prevalence was also found to have a significant

positive effect on the risk of iatrogenic HCV infection as a whole (p=0·031, Suppl Table S5). On the contrary, no overall association was found between HAQ level and risk of iatrogenic infection, while in procedure-specific analyses a negative significant impact of the HAQ level was observed for endoscopy only (p=0·016, Suppl Table S4).



***Figure 4*: Maps of risks of HCV infection for: (a) Blood transfusion (b) Surgery in various countries.** Brown points correspond to the number of observations used to compute a given pooled OR. Each country is coloured based on the value of the estimated OR following a light red to dark red colour gradient. Values of average estimates are reported as well as their 95% CI.

225 For blood transfusions performed before 1998, 17 studies were selected for the pooled OR calculation,
226 whereas there were 48 studies available for undated blood transfusions (Suppl Fig. S3 and S4). The
227 estimated pooled OR of HCV infection associated with blood transfusions performed before 1998 (OR
228 = 3·77 CI 95% [2·42-5·88]) was significantly higher than the pooled OR associated with undated blood
229 transfusions (2·28 [1·82-2·84], p = 0·046, Q =3·97)



230

231 ***Figure 5*: Forest plot reporting pooled OR estimates for HCV infection risk associated with**
232 **different groups of iatrogenic procedures for high HCV prevalence countries (>5%) vs. low**
233 **HCV prevalence countries (<5%)**. The high prevalence group includes Egypt, Pakistan and Mali.
234 Points correspond to average estimates and error bars correspond to 95% CI of these
235 estimates. The solid line represents the limit for which OR = 1 and the dotted line the average
236 value of the overall estimate. The total number of observations used for each pooled OR
237 calculation is specified in the column *N* and the heterogeneity for each estimation is depicted
238 in the column I^2. A given study could be used in the OR estimation of multiple procedures
239 groups. Procedures are sorted based on the value of their associated mean estimate, from the
240 highest to the lowest. There was no measure reported for transplantation in high HCV
241 prevalence countries. *: procedures for which a significant different was found between high
242 and low prevalence countries; Blanks within the I^2 column correspond to absence of
243 heterogeneity because of procedure group counting only one observation.

244 Across all studies, bias was low for most criteria, but some studies presented a potentially high risk of
245 bias for criteria related to exposure assessment and to potential confounding (Suppl Fig.S1 and Suppl
246 Table S2). No single study had high bias risk for all criteria. Nevertheless, the overall funnel plot showed
247 asymmetry and the associated Egger test was highly significant, suggesting potential publication bias
248 (Suppl Fig. S2).

249 Average ORs in non-cohort studies were found to be higher than in cohort studies (2·37 CI 95% [2·04-
250 2·75] vs. 1·92 [1·48-2·50]) but this difference was not significant (Q = 1·85, p = 0·17). Per-procedure
251 comparisons between cohort and non-cohort studies only showed a significant difference for the
252 transplantation (Q = 6·32, p = 0·012) and the injection (Q = 4·62, p = 0·032) group, for which cohort
253 studies was found to be associated with lower estimates.

254

255 **Discussion**

256 In this systematic review and meta-analysis, we identified 71 studies assessing the association between
257 hospital-based invasive procedures and the risk of HCV infection, representing a total of 120,734
258 participants. The overall strength of evidence remained of limited confidence as the bias analysis found
259 a lack of high-quality studies. Nevertheless, we estimated pooled ORs of HCV infection that were
260 significantly associated with most invasive procedures performed in hospitals. Our results suggest a
261 prioritization of iatrogenic procedures: haemodialysis was associated with the highest risk of HCV
262 infection whereas dental procedures and endoscopy were associated with the lowest risk. We also
263 underlined a large between-procedure and between-country variability, and showed that the per-
264 procedure risk tended to be higher in countries with high HCV prevalence, while the level of healthcare
265 quality and access in the country (as measured by the HAQ) only appeared to play a minor role.

266 The geographical coverage of selected studies was in line with global observed prevalence levels, with
267 a third of these studies coming from the two countries with the highest HCV prevalence worldwide
268 (Egypt and Pakistan). In addition, the most represented population was composed of haemodialysed
269 patients, for which the risk of HCV infection is historically high.[90] Regrettably, only few studies used
270 cohort data.

271 The estimated per-procedure risks seemed to be mostly in line with the available literature concerning
272 HCV. Generally, the risk was higher for procedures with frequent blood-contact.

273 First, although the associated confidence interval was wide, the highest OR estimate was found for
274 haemodialysis. HCV transmission commonly occurs within patients of the same dialysis unit, especially
275 when there is low compliance to recommended hygiene measures and recurrent contact with blood.[90]
276 In addition, the risk of HCV infection during this procedure is highly related to the duration of
277 haemodialysis.[91] Our estimate was lower, though compatible, than the one reported in the only
278 previous meta-analysis, published by El Ghitany et al in 2015.[13]

279 Surprisingly, we found a relatively high risk of infection linked to wound care, compared to other
280 procedures. The estimate of the HCV infection risk through sutures found by El Ghitany et al. was lower
281 than our estimate, but increased in the most recent studies.[13] The risk we found associated with organ
282 transplantation was also quite high, considering that most of countries now require HCV testing in
283 donors.[90] This might result from either lack of information on the procedure realization date or the
284 type of study design used to assess this risk, as it was found to be much lower considering only cohort
285 studies. Similarly, the intermediate risk we found for blood transfusion could be explained by the fact
286 that there is still high discrepancy in systematic screening of blood products between countries (only
287 80% of donations are screened in low-income countries).[92]

288 We found injection to be one of the lowest at-risk procedures. Iatrogenic injection was described in
289 the past as associated with a high risk of HCV infection, in particular because of the reuse of
290 contaminated syringes,[8] but this risk might have dropped over the last decade, in particular after the
291 publication of multiple WHO and CDC guidelines for safe injections.[93]

292 Finally, dental procedures and endoscopy were found to be the lowest risk groups, in line with current
293 literature findings. Indeed, only a few cases of HCV contamination after endoscopy have been
294 described and dental practices are often at low risk of contamination.[90,94] This result is also consistent
295 with previous estimations showing low risk associated with these two procedures.[13]

296 Country-level prevalence was overall found to be related to a higher risk of HCV contamination,
297 although it was only significantly associated with endoscopy and surgery risks when looking at specific

procedures. The lack of significance for other procedures may be explained in several ways. First, many countries were represented by less than 3 studies, leading to a lack of power for some procedures and countries and less accurate OR estimates. Second, these non-significant associations may also indicate the presence of other sources of heterogeneity. In particular, there may be high differences in terms of prevalence between hospital settings within the same country. Observed between-country variations may also result from different infection control practices; we explored this assumption using the HAQ index, which is internationally validated and available for all countries in our analysis. However, we found no significant relationship between the risk of getting HCV contaminated and this index, except for the risk linked to endoscopy. First, the HAQ index may not be the right indicator to accurately reflect compliance with infection control measures within hospitals. Second, there could be a high heterogeneity in this compliance between settings within the same country, that this index is unable to capture.

Our study carries several methodological as well as more study-related limitations.

First, no grey literature or papers in languages other than French or English were included in this review, resulting in a potential information loss. Some other methodological simplifications could have influenced our final results. In fact, pooling adjusted and non-adjusted measures could have led to overestimation of risks associated with some procedures. Our results also highly depend on the initial procedures classification we proposed, as homogeneity in terms of HCV infection risk cannot be assured. In particular, some procedures within the “other procedures” group might not imply a blood contact but this was not specified within selected articles.

This study highlighted several caveats in the existing literature. Bias analysis showed a lack of high-quality studies. On the one hand, 90% of studies presented at least a probably high bias concerning the assessment of exposure to hospital-based procedures, mostly using questionnaires to collect risk factors for HCV infection. This is consistent with the distribution of studies design, since almost 80% of studies were either cross-sectional or case-control studies. This over-representation of non-longitudinal designs may in particular have led to overestimated ORs of HCV infection associated with invasive iatrogenic procedures, due to differential recall bias between cases and controls. On the other hand, more than 50% of studies included a potential risk of bias due to incomplete or missing use of adjustment variables when estimating measures of association between HCV infection and iatrogenic procedures. Overall, heterogeneity in measures associated with iatrogenic procedures was shown and may reveal potential publication bias. In particular, non-significant risk measures might have been voluntarily neglected resulting, again, in an overestimation of the risk associated with these two groups of procedures.

For some procedure groups, only few data were available, which led to important uncertainty in the associated OR estimates. Half of procedure groups had less than ten risk measures, wound care being the procedure for which this number was the lowest with only five studies. Also, some procedures like surgery might have described operations during which multiple systematic procedures were performed and not taken into account (pre-surgical anaesthesia, …). More generally, we rarely had access to measures of risks associated with a unique realization of each procedure. Patients might have undergone the same procedure multiple times but this information was not taken into account. In particular, as mentioned previously, the risk of getting HCV infected during haemodialysis is highly related to the duration of haemodialysis and the risk related to blood transfusion is somehow positively proportional to the number of received transfusions.[95] These limitations may have caused overestimation of the risk associated with hospital-based procedures.

In addition, the date of realization of a procedure was not always available, and some measures might have been based on procedures performed a long time ago, thus leading again to an overestimation of the risk. Indeed, we found the pooled OR of blood transfusions performed before 1998 to be higher than that of undated blood transfusions, strongly suggesting that the risk was higher for older procedures - all the more so that the undated procedures could also have included old procedures.

In conclusion, despite the uncertainty in our estimates and the probable decrease in the general risk of HCV infection through hospital-based procedures over the last twenty years, this work shows that healthcare settings remain an important gateway of HCV infection and underline the importance of implementing efficient infection control.

Our results suggest a risk-based ranking for iatrogenic procedures, haemodialysis being the most at-risk procedure, and confirm the important role of blood screening in decreasing the risk of HCV infection. We also show that HCV infection risk tend to be higher in high prevalence countries. This could partly be explained by the high global heterogeneity in infection and prevention control knowledge in healthcare workers, especially concerning bloodborne pathogens. [96]

Two main tracks appear to be key to control HCV iatrogenic infections. First, knowledge of existing infection control measures should be improved in order to make them fully effective. Second, prevention efforts should be specifically targeted at high-risk procedures, such as haemodialysis, and in high HCV prevalence settings. In this regard, our work provides support to identify the procedures on which these efforts should be focused. Our results may also prove useful for future modelling studies assessing the effectiveness of control measures to limit HCV transmission in healthcare settings.

In 2016, the World Health Organization (WHO) set targets for global HCV elimination as a public health problem by 2030 – an 80% reduction in incidence and a 65% reduction in mortality from 2015 levels.[97] In order to reach these targets, high-prevalence countries such as Egypt and Pakistan have engaged in elimination programmes based on large-scale test-and-treat campaigns.[98] By helping efficiently scale up prevention interventions, our work has the potential to improve the cost-effectiveness of these campaigns, reaching the WHO targets faster and more easily.

Contributors

PH, KJ and LT conceived the study, wrote the protocol and data analysis plan. PH and MC screened the articles and conflicts were resolved by LT and KJ. Clinical input and HCV expertise were provided by LBLN and YS. PH did the statistical analysis. PH, LT and KJ interpreted the data. PH wrote the first draft of the report with input from LT, KJ, MC, LBLN and YS. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. PH, KJ and LT accessed and verified the data.

Data sharing

Data summary will be available in the supplementary appendix. The statistical analysis plan will be available with publication upon reasonable request to the corresponding author.

Declaration of interests

We declare no competing interests.

Acknowledgements

This study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), grant number 12320 B115.

References

1. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *WJG* 2016; **22**: 7824.

2. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide: Liver cancer attributable to hepatitis viruses worldwide. *Int J Cancer* 2018; **142**: 2471–7.

3. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization, 2021 https://apps.who.int/iris/handle/10665/341412 (accessed Oct 19, 2021).

4. Sapena V, Enea M, Torres F, *et al.* Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut* 2021; : gutjnl-2020-323663.

5. Latham NH, Doyle JS, Palmer AY, *et al.* Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. *Liver Int* 2019; **39**: 2244–60.

6. Nahon P, Layese R, Bourcier V, *et al.* Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. *Gastroenterology* 2018; **155**: 1436-1450.e6.

7. Trickey A, Fraser H, Lim AG, *et al.* The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. *The Lancet Gastroenterology & Hepatology* 2019; **4**: 435–44.

8. Frank C, Mohamed MK, Strickland GT, *et al.* The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *The Lancet* 2000; **355**: 887–91.

9. Sarman Singh, S. N. Dwivedi, Rita S. Hepatitis B, C and Human Immunodeficiency Virus Infections in Multiply-injected Kala-azar Patients in Delhi. *Scandinavian Journal of Infectious Diseases* 2000; **32**: 3–6.

10. Thompson ND. Nonhospital Health Care–Associated Hepatitis B and C Virus Transmission: United States, 1998–2008. *Ann Intern Med* 2009; **150**: 33.

11. Alduraywish A, Ragheb M, Taher I, Louis N, Aldossari K, Kishk R. Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study. *Scandinavian Journal of Gastroenterology* 2020; **55**: 963–9.

12. Arnold S, Melville SK, Morehead B, Vaughan G, Moorman A, Crist MB. *Notes from the Field:* Hepatitis C Transmission from Inappropriate Reuse of Saline Flush Syringes for Multiple Patients in an Acute Care General Hospital — Texas, 2015. *MMWR Morb Mortal Wkly Rep* 2017; **66**: 258–60.

13. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013); Do they differ in Egypt? *Liver Int* 2015; **35**: 489–501.

14. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org .

15. Médecins du Monde and Treatment Action Group. MapCrowd: online global data on hepatitis C. Available at: https://mapcrowd.org/

16. Fullman N, Yearwood J, Abay SM, *et al.* Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *The Lancet* 2018; **391**: 2236–71.

17. Lam J, Sutton P, Kalkbrenner A, *et al.* A Systematic Review and Meta-Analysis of Multiple Airborne Pollutants and Autism Spectrum Disorder. *PLoS ONE* 2016; **11**: e0161851.

18. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629–34.

19. AbdulQawi K, Youssef A, Metwally MA, Ragih I, AbdulHamid M, Shaheen A. Prospective study of prevalence and risk factors for hepatitis C in pregnant Egyptian women and its transmission to their infants. *Croat Med J* 2010; **51**: 219–28.

20. Akhtar AM, Khan MA, Ijaz T, *et al.* Hepatitis C virus infection in pregnant women in Lahore, Pakistan: An analytical cross sectional study. *Int J Agric Biol* 2014; **16**: 160–4.

21. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. *Nephrology (Carlton, Vic)* 2003; **8**: 256–60.

22. Amin Elzorkany KM, Zahran A. Hepatitis C virus status in hemodialysis patients in Menoufia Government, Egypt, five years apart: Do we have any improvement? *Saudi J Kidney Dis Transpl* 2017; **28**: 1126–32.

23. Amjad U, Ahmad SQ, Mir S, Ayub M. Association of anti-HCV sero-prevalence with blood transfusion and practice of haemodialysis from multiple centres in patients on maintenance haemodialysis. *Pakistan Journal of Medical Sciences* 2020; **36**: 286–9.

24. Asad M, Ahmed F, Zafar H, Farman S. Frequency and determinants of hepatitis B and C virus in general population of Farash Town, Islamabad. *Pak J Med Sci* 2015; **31**: 1394–8.

25. Asemahagn MA. Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia. *PloS one* 2020; **15**: e0234822.

26. Aslam A, Munawar I, Zahid N. Blood transfusion as a risk factor for hepatitis C in pregnancy. *Pak J Med Health Sci* 2016; **10**: 233–4.

27. Ba-Essa EM, Mobarak EI, Al-Daghri NM. Hepatitis C virus infection among patients with diabetes mellitus in Dammam, Saudi Arabia. *BMC health services research* 2016; **16**: 313.

28. Balew M, Moges F, Yismaw G, Unakal C. Assessment of hepatitis B virus and hepatitis C virus infections and associated risk factors in HIV infected patients at Debretabor hospital, South Gondar, Northwest Ethiopia. *Asian Pac J Trop Dis* 2014; **4**: 1–7.

29. Barut S, Barut S, Eğri M. Healthcare related risk factors account for the majority of HCV transmissions in middle black sea region of Turkey: A case-control study. *Turk Klinikleri J Med Sci* 2011; **31**: 142–7.

30. Beltrân M, Navas M-C, De La Hoz F, *et al.* Hepatitis C virus seroprevalence in multi-transfused patients in Colombia. *J Clin Virol* 2005; **34**: S33–8.

31. Bibi S, Dars S, Ashfaq S, Qazi RA, Akhund S. Seroprevalence and risk factors for hepatitis C virus (HCV) infection in pregnant women attending public sector tertiary care hospital in Hyderabad Sindh. *Pak J Med Sci* 2013; **29**.

32. Bouare B, Gothot A, Delwaide J, *et al.* Epidemiological profiles of human immunodeficiency virus and hepatitis C virus infections in malian women: Risk factors and relevance of disparities. *World J Hepatol* 2013; **5**: 196–205.

33. Calderon GM, Gonzalez-Velaquez F, Gonzalez-Bonilla CR, *et al.* Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. *Transfusion* 2009; **49**: 2200–7.

34. Calles DL, Collier MG, Khudyakov Y, *et al.* Hepatitis C virus transmission in a skilled nursing facility, North Dakota, 2013. *American Journal of Infection Control* 2017; **45**: 126–32.

35. da Silva NM, Germano FN, Mendoza-Sassi RA, Seuánez HN, Soares MA, de Martinez AM. Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. *Virology journal* 2013; **10**: 167.

36. De Oliveira AM, White KL, Leschinsky DP, *et al.* An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. *Ann Intern Med* 2005; **142**: 898-902+I – 38.

37. De Weggheleire A, An S, De Baetselier I, *et al.* A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. *Plos One* 2017; **12**.

38. Doblali T, Bahadi A, El Amrani M, Benyahia M. Prevalence and risk factors of hepatitis c virus infection in patients on hemodialysis: Results of a moroccan study. *Med Sante Tropica* 2014; **24**: 375–8.

39. Ejeta E, Dabsu R. Prevalence of hepatitis C virus and HIV infection among pregnant women attending antenatal care clinic in Western Ethiopia. *Front Med* 2019; **6**.

533 40. Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K. Prevalence and risk factors
534 of HCV infection in Poland. *Eur J Gastroenterol Hepatol* 2011; **23**: 1213–7.
535
536 41. Galperim B, Mattos AA, Stein AT, *et al.* Hepatitis C in hemodialysis: the contribution of injection
537 drug use. *Brazilian Journal of Infectious Diseases* 2010; **14**: 422–6.
538
539 42. Gasim GI, Hamdan HZ, Hamdan SZ, Adam I. Epidemiology of Hepatitis B and Hepatitis C Virus
540 Infections Among Hemodialysis Patients in Khartoum, Sudan. *Journal of Medical Virology* 2012;
541 **84**: 52–5.
542
543 43. Ghias M, Pewaiz MK, Marshall R, Thornley S. Identification of risk factors for Hepatitis C
544 infection in the Gujranwala District of Punjab, Pakistan. *World Appl Sci J* 2012; **20**: 94–101.
545
546 44. Haider J, Lufullah G, Nazli R, Akhtar T, Shah A. Screening of adult dental patients visiting Khyber
547 College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk
548 factors. *Pak J Med Sci* 2017; **33**: 615–20.
549
550 45. Hutton J, Doyle J, Zordan R, *et al.* Point-of-care Hepatitis C virus testing and linkage to
551 treatment in an Australian inner-city emergency department. *Int J Drug Policy* 2019; **72**: 84–
552 90.
553
554 46. Ishikawa T, Fukushima Y, Shiobara Y, *et al.* Outbreak of hepatitis C virus infection in an
555 outpatient clinic. *Journal of gastroenterology and hepatology* 2005; **20**: 1087–93.
556
557 47. Jaffery T, Tariq N, Ayub R, Yawar A. Frequency of hepatitis C in pregnancy and pregnancy
558 outcome. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP* 2005; **15**: 716–9.
559
560 48. Jamil Z, Waheed Y, Ahsan O, Najmi MH, Yousuf H. Familial clustering of hepatitis C virus in a
561 Pakistani population. *J Med Virol* 2020; **92**: 3499–506.
562
563 49. Jimenez AP, Mohamed MK, Eldin NS, *et al.* Injection Drug Use Is a Risk Factor for HCV Infection
564 in Urban Egypt. *Plos One* 2009; **4**.
565
566 50. Kandeel AM, Talaat M, Afifi SA, *et al.* Case control study to identify risk factors for acute
567 hepatitis C virus infection in Egypt. *Bmc Infectious Diseases* 2012; **12**.
568
569 51. Khalid GG, Kyaw KWY, Bousquet C, *et al.* From risk to care: The hepatitis C screening and
570 diagnostic cascade in a primary health care clinic in Karachi, Pakistan-a cohort study. *Int Health*
571 2019; **12**: 19–27.
572
573 52. Khan UR, Janjua NZ, Akhtar S, Hatcher J. Case-control study of risk factors associated with
574 hepatitis C virus infection among pregnant women in hospitals of Karachi-Pakistan. *Tropical*
575 *Medicine & International Health* 2008; **13**: 754–61.
576
577 53. Kim JY, Cho J, Hwang SH, *et al.* Behavioral and Healthcare-Associated Risk Factors for Chronic
578 Hepatitis C Virus Infection in Korea. *Journal of Korean Medical Science* 2012; **27**: 1371–7.
579
580 54. Kundu A, Mehta S, Agrawal BK, Singh VA. Assessment of associated risk factors in hepatitis B
581 virus and hepatitis C virus infections. *JK Science* 2017; **18**: 229–32.
582
583 55. Lioussfi Z, Errami Z, Radoui A, *et al.* Viral hepatitis C and B among dialysis patients at the Rabat
584 University Hospital: prevalence and risk factors. *Saudi J Kidney Dis Transpl* 2014; **25**: 672–9.

585
586 56. Loras C, Saro C, Gonzalez-Huix F, *et al.* Prevalence and factors related to hepatitis B and C in
587 inflammatory bowel disease patients in Spain: A nationwide, multicenter study. *Am J*
588 *Gastroenterol* 2009; **104**: 57–63.
589
590 57. Metwally A, Mohsen A, Saleh R, *et al.* Prioritizing high-risk practices and exploring new
591 emerging ones associated with hepatitis C virus infection in Egypt. *Iranian Journal of Public*
592 *Health* 2014; **43**: 1385–94.
593
594 58. Mittal G, Gupta P, Thakuria B, Mukhiya GK, Mittal M. Profile of Hepatitis B Virus, Hepatitis C
595 Virus, Hepatitis D Virus and Human Immunodeficiency Virus Infections in Hemodialysis
596 Patients of a Tertiary Care Hospital in Uttarakhand. *J Clin Exp Hepatol* 2013; **3**: 24–8.
597
598 59. Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C
599 infection among adult patients in Kedah state, Malaysia: A case-control study. *PloS one* 2019;
600 **14**: e0224459.
601
602 60. Mohsen A, Bernier A, Lefouler L, *et al.* Hepatitis C virus acquisition among Egyptians: Analysis
603 of a 10-year surveillance of acute hepatitis C. *Trop Med Int Health* 2015; **20**: 89–97.
604
605 61. Mostafa A, Ebeid FSE, Khaled B, Ahmed RHM, El-Sayed MH. Micro-elimination of hepatitis C
606 through testing of Egyptian pregnant women presenting at delivery: implications for screening
607 policies. *Trop Med Int Health* 2020; **25**: 850–60.
608
609 62. Murad EA, Babiker SM, Gasim GI, Rayis DA, Adam I. Epidemiology of hepatitis B and hepatitis
610 C virus infections in pregnant women in Sana'a, Yemen. *BMC Pregnancy Childbirth* 2013; **13**.
611
612 63. Neumeister AS, Pilcher LE, Erickson JM, *et al.* Hepatitis-C prevalence in an urban native-
613 American clinic: A prospective screening study. *Journal of the National Medical Association*
614 2007; **99**: 389–92.
615
616 64. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, *et al.* HCV iatrogenic and intrafamilial transmission
617 in Greater Cairo, Egypt. *Gut* 2010; **59**: 1554–60.
618
619 65. Patil SR, Datkhile KD, Ghorpade MV, Patil SS, Kakade SV. Seroprevalence, risk factors and
620 genotype distribution for Hepatitis C infection: A study from rural hospital in Maharashtra.
621 *Indian journal of medical microbiology* 2017; **35**: 563–7.
622
623 66. Prasad M, Saade GR, Sandoval G, *et al.* Hepatitis C Virus Antibody Screening in a Cohort of
624 Pregnant Women: Identifying Seroprevalence and Risk Factors. *Obstetrics and gynecology*
625 2020; **135**: 778–88.
626
627 67. Qureshi H, Arif A, Riaz K, Alam SE, Ahmed W. Determination of risk factors for hepatitis B and
628 C in male patients suffering from chronic hepatitis. *BMC Res Notes* 2009; **2**.
629
630 68. Ramsey SD, Unger JM, Baker LH, *et al.* Prevalence of Hepatitis B Virus, Hepatitis C Virus, and
631 HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community
632 Oncology Practices. *JAMA Oncol* 2019; **5**: 497–505.
633
634 69. Rosińska M, Parda N, Kołakowska A, *et al.* Factors associated with hepatitis C prevalence differ
635 by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-
636 2016. *PloS one* 2017; **12**: e0185055.

70. Ross RS, Viazov S, Clauberg R, *et al.* Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. *J Viral Hepatitis* 2009; **16**: 230–8.

71. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. *Bmc Gastroenterology* 2007; **7**.

72. Sahajian F, Vanhems P, Bailly F, Fabry J, Trepo C, Sepetjan M. Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France. *Eur J Public Health* 2007; **17**: 263–71.

73. Samimi-Rad K, Hosseini M, Mobeini G, *et al.* Hepatitis C virus infection among multi-transfused patients and personnel in haemodialysis units in central Islamic Republic of Iran. *East Mediterr Health J* 2012; **18**: 227–35.

74. Samimi-Rad K, Hosseini M, Shahbaz B. Hepatitis C virus infection and HCV genotypes of hemodialysis patients. *Iranian Journal of Public Health* 2008; **37**: 146–52.

75. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. *Haemophilia* 2007; **13**: 156–63.

76. Schmidt AJ, Rockstroh JK, Vogel M, *et al.* Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. *PloS one* 2011; **6**: e17781.

77. Senosy SA, El Shabrawy EM. Hepatitis C virus in patients on regular hemodialysis in Beni-Suef Governorate, Egypt. *The Journal of the Egyptian Public Health Association* 2016; **91**: 86–9.

78. Seong MH, Kil H, Kim YS, *et al.* Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. *Journal of medical virology* 2013; **85**: 1724–33.

79. Shahriari-Fard F, Alavian SM, Farajzadegan Z, Rabiei A, Ataei B, Ataie M. Assessment of hepatitis C risk factors in center of Iran: A case-control study. *J Res Med Sci* 2018; **23**.

80. Shimokura G, Chai F, Weber DJ, *et al.* Patient-care practices associated with an increased prevalence of hepatitis c virus infection among chronic hemodialysis patients. *Infect Control Hosp Epidemiol* 2011; **32**: 415–24.

81. Silva JL, de Souza VS, Vilella TA, Domingues AL, Coêlho MR. HBV and HCV serological markers in patients with the hepatosplenic form of mansonic schistosomiasis. *Arquivos de gastroenterologia* 2011; **48**: 124–30.

82. Sohn HS, Kim JR, Ryu SY, *et al.* Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with a. High Prevalence of HCV in the Republic of Korea in 2013. *Gut and Liver* 2016; **10**: 126–32.

83. Somi MH, Etemadi J, Ghojazadeh M, *et al.* Risk factors of HCV seroconversion in hemodialysis patients in Tabriz, Iran. *Hepatitis Mon* 2014; **14**.

84. Su Y, Yan R, Duan Z, *et al.* Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, China. *J Med Virol* 2013; **85**: 425–32.

85. Taye M, Daka D, Amsalu A, Hussen S. Magnitude of hepatitis B and C virus infections and associated factors among patients scheduled for surgery at Hawassa University comprehensive specialized Hospital, Hawassa City, southern Ethiopia. *BMC Res Notes* 2019; **12**.

86. Ullah M, Hasan F, Najmudin, *et al.* Seroprevalence of Hepatitis C virus infection in Kohat division, Khyber Pakhtoonkhwa, Pakistan. *Pak J Zool* 2016; **48**: 1721–5.

87. Ver Hoeve E, Codlin AJ, Jawed F, *et al.* Persisting role of healthcare settings in hepatitis C transmission in Pakistan: cause for concern. *Epidemiology and infection* 2013; **141**: 1831–9.

88. Vidales-Braz BM, Da Silva NMO, Lobato R, *et al.* Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: Prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. *Virol J* 2015; **12**.

89. Weisbord JS, Trepka MJ, Zhang G, Smith IP, Brewer T. Prevalence of and risk factors for hepatitis C virus infection among STD clinic clientele in Miami, Florida. *Sexually transmitted infections* 2003; **79**: E1.

90. Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C virus infection. *World J Gastroenterol* 2014; **20**: 17265–78.

91. Sun J, Yu R, Zhu B, Wu J, Larsen S, Zhao W. Hepatitis C Infection and Related Factors in Hemodialysis Patients in China: Systematic Review and Meta-Analysis. *Renal Failure* 2009; **31**: 610–20.

92. World Health Organization. Blood safety and availability (fact sheet, 2021). Retrieved from: https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

93. Defendorf CM, Paul S, Scott GJ. Iatrogenic Hepatitis C Virus Transmission and Safe Injection Practices. *J Am Osteopath Assoc* 2018; **118**: 311.

94. Morris J, Duckworth GJ, Ridgway GL. Gastrointestinal endoscopy decontamination failure and the risk of transmission of blood-borne viruses: a review. *Journal of Hospital Infection* 2006; **63**: 1–13.

95. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review. *Journal of Hepatology* 2006; **45**: 607–16.

96. Alhumaid S, Al Mutair A, Al Alawi Z, *et al.* Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review. *Antimicrob Resist Infect Control* 2021; **10**: 86.

97. World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization. https://apps.who.int/iris/handle/10665/246177 (accessed Oct 19, 2021)

98. Lim AG, Qureshi H, Mahmood H, *et al.* Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. *International Journal of Epidemiology* 2018; **47**: 550–60.